Showing results (41-50 of 203) with videos related to
Sort By:
Pageof 21
Antiviral Therapy|January 17, 2017
Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeksDanielle P Porter, Rima Kulkarni, Will Garner, et al.HIV Clinical Trials|March 18, 2015
96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjectsDanielle P Porter, Rima Kulkarni, Todd Fralich, et al.Journal of Clinical Microbiology|March 8, 2005
Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutationJan Weber, Bikram Chakraborty, Jitka Weberova, et al.Journal of Virology|March 9, 2002
Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusionJanet E Lineberger, Renee Danzeisen, Daria J Hazuda, et al.Plos One|August 12, 2014
Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapyRichard M Gibson, Jan Weber, Dane Winner, et al.Journal of Clinical Microbiology|July 1, 2011
Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samplesAndrew S Bae, Karin S Ku, Michael D Miller, et al.Antiviral Therapy|June 9, 2006
In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabineKatyna Borroto-Esoda, Jennifer E Vela, Florence Myrick, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 1, 2009
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934Nicolas A Margot, Jeff Enejosa, Andrew K Cheng, et al.Antiviral Therapy|July 28, 2012
Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010Michael D Miller, Mojgan Haddad, Cathy Su, et al.HIV Clinical Trials|September 12, 2017
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128)Rima Kulkarni, Sally L Hodder, Huyen Cao, et al.Pageof 21